Monday, May 6, 2013OXiGENE Reports First Quarter 2013 Financial Results
Wednesday, April 24, 2013OXiGENE Announces Completion of Enrollment of ZYBRESTAT(R) Phase 2 Ovarian Cancer Trial
Product Pipeline
OXiGENE Clinical Trials
Investor Center